The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     
6 pts

Opinion on  Generex Biotechnology Corp (GNBT)     Sector: Healthcare  >  Industry: Biotechnology & Drugs
Bullish on GNBT ...

Nov 09, 2007 10:08 PM GMT
Return Risk
-65.43% HIGH
Analyst

Product Review  

With Pfizer dropping Exubra, Generex's Oral-lyn has very little competition in the non-injectable insulin delivery market. India is now on board with Oral-lyn and 5 other countries are expected to approve it by year's end. This will bring much needed revenue beginning early next year. Generex is also expecting positive news on its cancer vaccines by end of '07 (Antigen Express).


GNBT:  This call was made on 11/09/07 @ $1.62
Rating:   Positive   $1.62 (11/09/07)
Gain/Loss:   -65.43% in 756 days
Target:   $4.00 (+146.91%) in Six months
Allocation:   100.0% of portfolio


Comments (1)

Add Comment

Arrow_up
Arrow_down
taldrkhandsme2003   N/A     1 point   commented 542 days ago reply

Oddly enough, the vaccine portion of Generex is what put GNBT on the investment map in the first place. The possiblity of an Avian Flu vaccine ran the stock price up dramatically during a distraction tactic used by "W" during a particularly contentious time in the Iraq war. The Pres. decided that bird flu would preoccupy the press for a while and right he was. No matter. Many investors were introduced to this dymanic company who would otherwise never have heard of it.


Your Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 21.10 +34.44% 381
2 18.14 +71.24% 211
3 17.66 +25.60% 55
4 13.47 +14.32% 62
5 12.13 +74.22% 40


POPULAR STOCKS
Symbol Company Name Sentiment

TODAY'S HEADLINES

TODAY'S TOP PICKS

 
Generex Biotechnology Corp (GNBT)
   SocialPicks Sentiment:   

   This Quarter's Sentiment:
All:
96.5%
Top:
100.0%




Latest Picks by deebz
Symbol SP Sentiment Rating Return Since

View All >
   




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch